Document is current
Any future updates will be listed below
-
Authors
Launay, Agathe
Carvalho, Kevin
Genin, Athénais
Gauvrit, Thibaut
Nobili, Paola
Gomez-Murcia, Victoria
Augustin, Emma
Burgard, Anaëlle
Gambi, Johanne
Fourmy, Déborah
Thiroux, Bryan
Vieau, Didier
Bemelmans, Alexis-Pierre https://orcid.org/0000-0001-7605-5225
Le Gras, Stephanie https://orcid.org/0000-0001-6293-6507
Buée, Luc https://orcid.org/0000-0002-6261-4230
Orr, Miranda E.
Audinat, Etienne https://orcid.org/0000-0002-6389-422X
Boutillier, Anne-Laurence https://orcid.org/0000-0002-2317-9280
Bonvento, Gilles https://orcid.org/0000-0002-2886-4228
Cambon, Karine
Faivre, Emilie
Blum, David https://orcid.org/0000-0001-5691-431X
-
Funding
Funding for this research was provided by:
Agence Nationale de la Recherche
Fondation pour la Recherche Médicale
- License Information
-
More Information
Article History
Received: 23 July 2024
Revised: 13 June 2025
Accepted: 8 July 2025
First Online: 23 July 2025
Competing interests
: DB is a (non-appointed) member of the scientific advisory board of Marvel Biosciences Corp developing an A 2A R antagonist. But there is no conflict of interest regarding the present work. Other authors have no competing financial interests in relation to the work described.
